Drivetime Radio Productions

As the use of TAVI expands into younger and lower-risk populations, long-term durability and clinical outcomes are at the forefront of decision-making.

In these two new Drivetime interviews, A/Prof. Justin Mariani speaks with leading interventional cardiologists to examine 5-year data from the Evolut Low Risk trial and its implications for contemporary Australian practice.

<< Login to stream the interviews below or access our private podcast. If you don’t have a login, subscribe for free now! >>

 

TAVI in Low-Risk Patients (VIC Perspective)

TAVI in Low-Risk Patients: Interpreting 5-Year Data Through Two Clinical Lenses (VIC Perspective)
34-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

As the use of TAVI expands into younger and lower-risk populations, long-term durability and clinical outcomes are at the forefront of decision-making.

In this interview A/Prof. Justin Mariani speaks with a leading interventional cardiologist from Melbourne, to examine 5-year data from the Evolut Low Risk trial and its implications for contemporary Australian practice.

They discuss the evolving evidence, valve durability, and haemodynamics, and how the latest findings are reshaping referral pathways, shared decision-making and patient selection.

Host

Associate Professor Justin Mariani

Associate Professor & Cardiologist, The Alfred Hospital, Melbourne.

Guest Experts

  • Professor Tony Walton

    Professor Tony Walton

    Structural Interventionist, Deputy Director of the Alfred Hospital.


TAVI in Low-Risk Patients (NSW Perspective)

TAVI in Low-Risk Patients: Interpreting 5-Year Data Through Two Clinical Lenses (NSW Perspective)
25-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

As the use of TAVI expands into younger and lower-risk populations, long-term durability and clinical outcomes are at the forefront of decision-making.

In this interview A/Prof. Justin Mariani speaks with a leading interventional cardiologist from Sydney, to examine 5-year data from the Evolut Low Risk trial and its implications for contemporary Australian practice.

They discuss the evolving evidence, valve durability, and haemodynamics, and how the latest findings are reshaping referral pathways, shared decision-making and patient selection.

Host

Associate Professor Justin Mariani

Associate Professor & Cardiologist, The Alfred Hospital, Melbourne.

Guest Experts

  • Prof. David Muller

    Prof. David Muller

    Cardiologist, St Vincent’s Hospital, Sydney.


Log in

You must login or join to access this content

×

Tap the share icon ios share icon and select 'Add to Home Screen' to add the site to your home screen for quick access!